(Q43221788)

16 November 2017

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia (English)

1 reference

16 November 2017

1 reference

1

K Schmiegelow

1 reference

16 November 2017

E Forestier

2

1 reference

16 November 2017

M Hellebostad

3

1 reference

16 November 2017

M Heyman

4

1 reference

16 November 2017

J Kristinsson

5

1 reference

16 November 2017

S Söderhäll

6

1 reference

16 November 2017

M Taskinen

7

1 reference

16 November 2017

Nordic Society of Paediatric Haematology and Oncology

8

1 reference

16 November 2017

10 December 2009

1 reference

16 November 2017

1 reference

16 November 2017

24

1 reference

16 November 2017

345-354

1 reference

16 November 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2009.251

16 November 2017

0 references

cites work

Acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

A population-based study of childhood acute lymphoblastic leukemia diagnosed from July 1981 through June 1985 in the five Nordic countries. Incidence, patient characteristics and treatment results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Dic(9;20)(p13;q11) in childhood acute lymphoblastic leukaemia is related to low cellular resistance to asparaginase, cytarabine and corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

High incidence of the ETV6/RUNX1 fusion gene in paediatric precursor B-cell acute lymphoblastic leukaemias with trisomy 21 as the sole cytogenetic change: a Nordic series of cases diagnosed 1989-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

High incidence of secondary brain tumours after radiotherapy and antimetabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Current management and challenges of malignant disease in the CNS in paediatric leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Allogeneic transplantation for childhood ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Minimal residual disease in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.251

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.251

1 reference

Dimensions Publication ID

16 November 2017

0 references

1 reference